

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**April 1, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Dyax Corp.**

**File No. 000-24537 - CF# 29076**

---

Dyax Corp. submitted an application under Rule 24b-2 requesting extensions of previous grants of confidential treatment for information it excluded from Exhibit 10.20 to a Form 10-K filed on March 12, 2010, Exhibit 10.1 to a Form 10-Q filed on November 3, 2011 and Exhibits 10.8(b) and 10.8(c) to a Form 10-K filed on March 2, 2012. Exhibit 10.20 was refiled with fewer redactions as Exhibit 10.2 to a Form 8-K filed on March 29, 2013.

Based on representations by Dyax Corp. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

<b>Exhibit</b>	<b>Form</b>	<b>Filed</b>	<b>Confidential Treatment Granted</b>
10.20	10-K	March 12, 2010	through November 19, 2014
10.1	10-Q	November 3, 2011	through November 19, 2014
10.8(b)	10-K	March 2, 2012	through November 19, 2014
10.8(c)	10-K	March 2, 2012	through November 19, 2014
10.2	8-K	March 29, 2013	through November 19, 2014

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Michael Seaman  
Special Counsel